United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

1:41pm EDT
Change (% chg)

$-0.11 (-0.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bloom, Floyd 

Dr. Floyd E. Bloom M.D. is Independent Director of Alkermes Plc. He was a founder of Alkermes, Inc. and has been active in neuropharmacology for more than 35 years, holding positions at was a founder of Alkermes, Inc. and has been active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health, The Salk Institute, and The Scripps Research Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and is now Professor Emeritus. Dr. Bloom served as Editor-in-Chief of Science from 1995 to May 2000. He is a member of the National Academy of Science, the Institute of Medicine, the Royal Swedish Academy of Science and the American Philosophical Society. He is an Emeritus Trustee for the Board of Trustees at Washington University in St. Louis. Dr. Bloom is a director of AgeneBio, Inc. a privately held biopharmaceutical company. Dr. Bloom also serves on the Scientific Advisory Boards of aTyr Pharma, a privately held pharmaceutical company and RiverVest, a private venture partnership focusing on life sciences. Dr. Bloom served as a member of the board of directors of Elan from 2007 to 2009. Qualifications and Skills: Dr. Bloom is a distinguished scientist and long-standing member of various scientific societies, including the National Academy of Sciences. His scientific knowledge makes him a resource to our research and development and commercial teams and a reference point for other directors. Dr. Bloom's service on other company boards provides experience relevant to good corporate governance practices. As a founder of Alkermes, Inc., Dr. Bloom brings a historical perspective to the Board.

Basic Compensation

Total Annual Compensation, USD 89,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 370,642
Fiscal Year Total, USD 459,642

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops


Shane Cooke


James Frates


Kathryn Biberstein


Elliot Ehrich


Michael Landine

As Of  30 Dec 2015